Ferrazzi Anna, Russo Irene, Pasello Giulia, Alaibac Mauro
Dermatology Unit, Department of Medicine, University of Padua, Padua I-35121, Italy.
Unit of Medical Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua I-35128, Italy.
Exp Ther Med. 2016 Jan;11(1):197-200. doi: 10.3892/etm.2015.2881. Epub 2015 Nov 19.
Gefitinib is a selective epidermal growth factor receptor tyrosine kinase inhibitor utilized for the treatment of advanced non-small cell lung carcinoma. The most commonly reported adverse event during gefitinib therapy is skin rash, particularly a papulopustular acne-like eruption. Cutaneous toxicities can affect treatment compliance and the quality of life of the patient. The present study reports a case of gefitinib-induced atypical skin reaction in a 73-year-old woman with advanced non-small cell lung cancer, who developed a squamous-crusted eruption on her face after 4 weeks of oral treatment with gefitinib at a dose of 250 mg/day. The patient was treated with 100 mg minocyclin (2 tablets/day, orally) and with ryfamicin topically. A complete resolution of the lesions was observed 2 weeks later. The present case report explored the pathogenesis of this skin manifestation, focusing on the underlying immunological mechanisms. A review of the literature concerning skin reactions to gefitinib was also conducted.
吉非替尼是一种用于治疗晚期非小细胞肺癌的选择性表皮生长因子受体酪氨酸激酶抑制剂。吉非替尼治疗期间最常报告的不良事件是皮疹，尤其是丘疹脓疱样痤疮样皮疹。皮肤毒性会影响治疗依从性和患者的生活质量。本研究报告了一例73岁晚期非小细胞肺癌女性患者出现吉非替尼诱导的非典型皮肤反应的病例，该患者在口服剂量为250mg/天的吉非替尼4周后，面部出现鳞状结痂皮疹。患者接受了100mg米诺环素（每天2片，口服）和利福平局部治疗。2周后观察到皮损完全消退。本病例报告探讨了这种皮肤表现的发病机制，重点关注潜在的免疫机制。还对有关吉非替尼皮肤反应的文献进行了综述。
